Skip to main content
. 2022 Feb 6;24(6):1066–1076. doi: 10.1002/ejhf.2433

Figure 2.

EJHF-2433-FIG-0002-c

Effect of dapagliflozin compared with placebo on the primary composite outcome, cardiovascular death, heart failure hospitalization and all‐cause mortality according to baseline uric acid level (fractional polynomial analysis), displayed as a hazard ratio in the solid black line with the shaded area representing 95% confidence intervals. The interrupted red line represents the line of null effect (i.e. hazard ratio of 1.00), below which the estimates favour dapagliflozin. Treatment effect for each outcome (except all‐cause mortality) adjusted for history of heart failure hospitalization and stratified by diabetes status.